Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with neoadjuvant TPF chemotherapy for resectable locally advanced head and neck squamous cell carcinoma
ChiCTR2200060564Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Apr 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab, docetaxel, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by Xijing Hospital. Primary endpoint: Objective response rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
nimotuzumabdocetaxelcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200060564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060564.